Csl (QX) Stock Quote CSLLY - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

100.02

Bid

99.26

Ask

100.17

Volume

27,604

97.72 Day's Range 101.08

71.51 52 Week Range 109.00

Market Cap

96.67B

Previous Close

100.606

Open

101.08

Last Trade

100.02

Last Trade Time

Financial Volume

$ 2,746,721

VWAP

99.5044

Average Volume (3m)

21,569

Shares Outstanding

966,505,458

Dividend Yield

PE Ratio

114.87

Earnings Per Share (EPS)

2.73

Revenue

14.69B

Net Profit

2.64B

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.csl.com.au

Headquarters

Melbourne, Victoria, Aus

Founded

1916

Csl Ltd (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker CSLLY. The last closing price for Csl (QX) was $100.61. Over the last year, Csl (QX) shares have traded in a share price range of $ 71.51 to $ 109.00.

Csl (QX) currently has 966,505,458 shares outstanding. The market capitalization of Csl (QX) is $97.24 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 114.87.

FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

Form 3 - Initial statement of beneficial ownership of securities

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for Neurological Disorders PR Newswire KING OF PRUSSIA, Pa...

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO, June 24, 2015 - Data supports prolonged dosing...

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24, 2015 Data Presented during Late Breaking Session at...

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how value of biopharmaceutical technologies is assessed...

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More than 20 abstracts focusing on investigational and...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) PR Newswire KING OF...

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring Recognized for its Longstanding Commitment to Delivering Innovative Products and Programs that...

Science, Information, And Technology Driving Evolution Of Global Healthcare

Science, Information, And Technology Driving Evolution Of Global Healthcare Industry serves critical role in advancing healthcare and improving the well-being of patients, says CSL CEO Paul...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.505	-0.502362596369	100.525	105.66	97.72	20689	101.17471525	DR
4	-5.305	-5.03679088535	105.325	109	95.05	21227	102.86766378	DR
12	1.94	1.9779771615	98.08	109	95.05	21569	101.34837941	DR
26	8.37	9.1325695581	91.65	109	85.96	28790	95.32155483	DR
52	14.02	16.3023255814	86	109	71.51	48040	87.97511129	DR
156	-10.86	-9.79437229437	110.88	117.24	71.51	64016	92.85834302	DR
260	19.29	23.8944630249	80.73	117.98	71.51	56806	95.86719208	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GIPLGlobal Innovative Platforms Inc (CE)	$ 0.10 (9,999,900.00%)	605
ZHCLFZenith Capital Corporation (CE)	$ 0.07 (6,999,900.00%)	5.54k
AUSAFAustralis Capital Inc (CE)	$ 0.0101 (1,009,900.00%)	9.26k
ZAAGZA Group Inc (PK)	$ 0.0001 (9,900.00%)	512.76k
NWPNNow Corp (PK)	$ 0.0001 (9,900.00%)	5.76M
PFTIPuradyn Filter Technologies Inc (CE)	$ 0.000001 (-99.96%)	200k
GENNGenesis Healthcare Inc (CE)	$ 0.000001 (-99.91%)	2k
ATHXQAthersys Inc New (CE)	$ 0.000001 (-99.90%)	968
STIXFSemantix Inc (CE)	$ 0.0002 (-99.88%)	1.76k
GOSYGeckosystems International Corp (CE)	$ 0.000001 (-99.33%)	1M
AAPJAAP Inc (PK)	$ 0.0003 (-40.00%)	559.12M
AMLHAmerican Leisure Holdings Inc (PK)	$ 0.0003 (0.00%)	142.01M
ASIIAccredited Solutions Inc (PK)	$ 0.0006 (0.00%)	108.17M
HMBLHUMBL Inc (PK)	$ 0.00015 (50.00%)	100.64M
HCMCHealthier Choices Management Corporation (PK)	$ 0.000001 (-98.00%)	95.68M